Roles of nucleus accumbens CREB and dynorphin in dysregulation of motivation

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 2, 2013, Pages

  Muschamp, John W ^a   Carlezon, William A ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE UPTAKE INHIBITOR; DYNORPHIN; MORPHINE; NARCOTIC AGENT; NEUROTRANSMITTER RECEPTOR;

ADDICTION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MAMMAL; MOTIVATION; NUCLEUS ACCUMBENS; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; REWARD; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; COCAINE; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DOPAMINE UPTAKE INHIBITORS; DYNORPHINS; GENE EXPRESSION REGULATION; HUMANS; MAMMALS; MORPHINE; MOTIVATION; NARCOTICS; NUCLEUS ACCUMBENS; RECEPTORS, NEUROTRANSMITTER; REWARD; SIGNAL TRANSDUCTION; SUBSTANCE-RELATED DISORDERS; TRANSCRIPTIONAL ACTIVATION;

MLCS; MLOWN;

EID: 84878959430     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a012005     Document Type: Article

References (139)

1. Altarejos J.Y., Montminy M. 2011. CREB and the CRTC coactivators: Sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol 12: 141-151.
2. Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS. 1993. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 264: 489-495.
3. Bannister A.J., Kouzarides T. 1996. The CBP co-activator is a histone acetyltransferase. Nature 384: 641-643.
4. Beardsley P.M., Howard JL, Shelton KL, Carroll FI. 2005. Differential effects of the novel κ opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl) 183: 118-126.
5. Berton O., McClung CA, Dileone RJ, Krishnan V, RenthalW, Russo S.J., GrahamD, Tsankova NM, Bolanos CA, Rios M, et al. 2006. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311: 864-868.
6. Brischoux F., Chakraborty S, Brierley DI, Ungless MA. 2009. Phasic excitation of dopamine neurons in ventral VTA by noxious stimuli. Proc Natl Acad Sci 106: 4894-4899.
7. Bruchas M.R., Land BB, Lemos JC, Chavkin C. 2009. CRF1-R activation of the dynorphin/κ opioid system in the mouse basolateral amygdala mediates anxiety-like behavior. PLoS ONE 4: e8528.
8. Bruchas M.R., Schindler AG, Shankar H, Messinger DI, Miyatake M., Land BB, Lemos JC, Hagan CE, Neumaier JF, Quintana A, et al. 2011. Selective p38αMAPKdeletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron 71: 498-511.
9. Carlezon W.A., Chartoff EH. 2007. Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc 2: 2987-2995.
10. Carlezon WA Jr, Thomas MJ. 2009. Biological substrates of reward and aversion: A nucleus accumbens activity hypothesis. Neuropharmacology 56 (Suppl 1): 122-132.
11. Carlezon WA Jr, Devine DP, Wise RA. 1995. Habit-forming actions of nomifensine in nucleus accumbens. Psychopharmacology (Berl) 122: 194-197.
12. Carlezon WA Jr, Thome J, Olson VG, Lane-Ladd SB, Brodkin ES, Hiroi N, Duman RS, Neve RL, Nestler EJ. 1998. Regulation of cocaine reward by CREB. Science 282: 2272-2275.
13. Carlezon WA Jr, Duman RS, Nestler EJ. 2005. The many faces of CREB. Trends Neurosci 28: 436-445.
14. Carlezon WA Jr, Beguin C, DiNieri JA, Baumann MH, Richards M.R., Todtenkopf MS, Rothman RB, Ma Z, Lee DY, Cohen BM. 2006. Depressive-like effects of the κopioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316: 440-447.
15. Chambers R.A., Bickel WK, Potenza MN. 2007. A scale-free systems theory of motivation and addiction. Neurosci Biobehav Rev 31: 1017-1045.
16. Chartoff E.H., Papadopoulou M, MacDonald ML, Parsegian A, Potter D, Konradi C, Carlezon WA Jr. 2009. Desipramine reduces stress-activated dynorphin expression and CREB phosphorylation in NAc tissue. Mol Pharmacol 75: 704-712.
17. Chartoff E., Sawyer A, Rachlin A, Potter D, Pliakas A, CarlezonWA. 2012. Blockade of κ opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology 62: 167-176.
18. Chavkin C., James IF, Goldstein A. 1982. Dynorphin is a specific endogenous ligand of the κ opioid receptor. Science 215: 413-415.
19. Chen J., Kelz MB, Zeng G, Sakai N, Steffen C, Shockett PE, Picciotto M.R., Duman RS, Nestler EJ. 1998. Transgenic animals with inducible, targeted gene expression in brain. Mol Pharmacol 54: 495-503.
20. Chrivia J.C., Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH. 1993. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365: 855-859.
21. Coffey S.F., Dansky BS, Carrigan MH, Brady KT. 2000. Acute and protracted cocaine abstinence in an outpatient population: A prospective study of mood, sleep and withdrawal symptoms. Drug Alcohol Depend 59: 277-286.
22. Cole R.L., Konradi C, Douglass J, Hyman SE. 1995. Neuronal adaptation to amphetamine and dopamine: Molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron 14: 813-823.
23. Conkright M.D., Canettieri G, Screaton R, Guzman E, Miraglia L, Hogenesch JB, Montminy M. 2003. TORCs: Transducers of regulated CREB activity. Mol Cell 12: 413-423.
24. Covington HE III, Maze I, Sun H, Bomze HM, DeMaio KD, Wu E.Y., Dietz DM, Lobo MK, Ghose S, Mouzon E, et al. 2011. A role for repressive histone methylation in cocaine-induced vulnerability to stress. Neuron 71: 656-670.
25. Crawford C.A., McDougall SA, Bolanos CA, Hall S, Berger SP. 1995. The effects of the κ agonist U-50,488 on cocaineinduced conditioned and unconditioned behaviors and Fos immunoreactivity. Psychopharmacology (Berl) 120: 392-399.
26. Daunais J.B., Roberts DC, McGinty JF. 1995. Short-term cocaine self administration alters striatal gene expression. Brain Res Bull 37: 523-527.
27. Degenhardt L., Hall W. 2012. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 379: 55-70.
28. Devine D.P., Leone P, Pocock D, Wise RA. 1993. Differential involvement of ventral tegmental m, δ and κ opioid receptors in modulation of basal mesolimbic dopamine release: In vivo microdialysis studies. J Pharmacol Exp Ther 266: 1236-1246.
29. Dinieri J.A., Nemeth CL, Parsegian A, Carle T, Gurevich VV, Gurevich E., Neve RL, Nestler EJ, Carlezon WA Jr. 2009. Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens. J Neurosci 29: 1855-1859.
30. Dong Y., Green T, Saal D, Marie H, Neve R, Nestler EJ, Malenka RC. 2006. CREB modulates excitability of nucleus accumbens neurons. Nat Neurosci 9: 475-477.
31. Donzanti B.A., Althaus JS, Payson MM, Von Voigtlander PF. 1992. κ Agonist-induced reduction in dopamine release: Site of action and tolerance. Res Commun Chem Pathol Pharmacol 78: 193-210.
32. Durieux P.F., Bearzatto B, Guiducci S, Buch T, Waisman A, Zoli M., Schiffmann SN, de Kerchove d'Exaerde A. 2009. D2R striatopallidal neurons inhibit both locomotor and drug reward processes. Nat Neurosci 12: 393-395.
33. Ferreri K., Gill G, Montminy M. 1994. The cAMP-regulated transcription factor CREB interacts with a component of the TFIID complex. Proc Natl Acad Sci 91: 1210-1213.
34. Ford C.P., Mark GP, Williams JT. 2006. Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J Neurosci 26: 2788-2797.
35. Foulkes N.S., Borrelli E, Sassone-Corsi P. 1991. CREM gene: Use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. Cell 64: 739-749.
36. Gerfen C.R., Surmeier DJ. 2011. Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 34: 441-466.
37. Ghazizadeh A., Ambroggi F, Odean N, Fields HL. 2012. Prefrontal cortex mediates extinction of responding by two distinct neural mechanisms in accumbens shell. J Neurosci 32: 726-737.
38. Glick S.D., Maisonneuve IM, Raucci J, Archer S. 1995. κ Opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 681: 147-152.
39. Gonzalez G.A., Montminy MR. 1989. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59: 675-680.
40. Graham D.L., Edwards S, Bachtell RK, DiLeone RJ, Rios M, Self DW. 2007. Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse. Nat Neurosci 10: 1029-1037.
41. Groenewegen H.J., Wright CI, Beijer AV. 1996. The nucleus accumbens: Gateway for limbic structures to reach the motor system? Prog Brain Res 107: 485-511.
42. Haberny S.L., Carr KD. 2005. Comparison of basal and D-1 dopamine receptor agonist-stimulated neuropeptide gene expression in caudate-putamen and nucleus accumbens of ad libitum fed and food-restricted rats. Brain Res Mol Brain Res 141: 121-127.
43. Hagiwara M., Alberts A, Brindle P, Meinkoth J, Feramisco J, Deng T., Karin M, Shenolikar S, Montminy M. 1992. Transcriptional attenuation following cAMP induction requires PP-1-mediated dephosphorylation of CREB. Cell 70: 105-113.
44. Hagiwara M., Brindle P, Harootunian A, Armstrong R, Rivier J, Vale W, Tsien R, Montminy MR. 1993. Coupling of hormonal stimulation and transcription via the cyclic AMP-responsive factor CREB is rate limited by nuclear entry of protein kinase A. Mol Cell Biol 13: 4852-4859.
45. Han W, Takamatsu Y, Yamamoto H, Kasai S, Endo S, Shirao T, Kojima N, Ikeda K. 2011. Inhibitory role of inducible cAMP early repressor (ICER) in methamphetamine-induced locomotor sensitization. PLoS ONE 6: e21637.
46. Hobert O., Carrera I, Stefanakis N. 2010. The molecular and gene regulatory signature of a neuron. TrendsNeurosci 33: 435-445.
47. Hoebel B.G., Monaco AP, Hernandez L, Aulisi EF, Stanley BG, Lenard L. 1983. Self-injection of amphetamine directly into the brain. Psychopharmacology (Berl) 81: 158-163.
48. Hollander J.A., Im HI, Amelio AL, Kocerha J, Bali P, Lu Q, Willoughby D., Wahlestedt C, Conkright MD, Kenny PJ. 2010. Striatal microRNA controls cocaine intake through CREB signalling. Nature 466: 197-202.
49. Huang Y.H., Lin Y, Brown TE, Han MH, Saal DB, Neve RL, Zukin R.S., Sorg BA, Nestler EJ, Malenka RC, et al. 2008. CREB modulates the functional output of nucleus accumbens neurons: A critical role of N-methyl-D-aspartate glutamate receptor (NMDAR) receptors. J Biol Chem 283: 2751-2760.
50. Hurd Y.L., Herkenham M. 1993. Molecular alterations in the neostriatum of human cocaine addicts. Synapse 13: 357-369.
51. Hurd Y.L., Brown EE, Finlay JM, Fibiger HC, Gerfen CR. 1992. Cocaine self-administration differentially alters mRNA expression of striatal peptides. Brain Res Mol Brain Res 13: 165-170.
52. Ikemoto S., Panksepp J. 1999. The role of nucleus accumbens dopamine in motivated behavior: A unifying interpretation with special reference to reward-seeking. Brain Res Brain Res Rev 31: 6-41.
53. Ikemoto S., Wise RA. 2004. Mapping of chemical trigger zones for reward. Neuropharmacology 47 (Suppl 1): 190-201.
54. Impey S., McCorkle SR, Cha-Molstad H, Dwyer JM, Yochum GS, Boss JM, McWeeney S, Dunn JJ, Mandel G, Goodman RH. 2004. Defining the CREB regulon: A genomewide analysis of transcription factor regulatory regions. Cell 119: 1041-1054.
55. Jackson D.M., Anden NE, Dahlstrom A. 1975. A functional effect of dopamine in the nucleus accumbens and in some other dopamine-rich parts of the rat brain. Psychopharmacologia 45: 139-149.
56. Jackson K.J., Carroll FI, Negus SS, Damaj MI. 2010. Effect of the selective κ-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse. Psychopharmacology (Berl) 210: 285-294.
57. Joseph M.H., Datla K, Young AM. 2003. The interpretation of the measurement of nucleus accumbens dopamine by in vivo dialysis: The kick, the craving or the cognition? Neurosci Biobehav Rev 27: 527-541.
58. Kampman KM. 2010. What's new in the treatment of cocaine addiction? Curr Psychiatry Rep 12: 441-447.
59. Kauer J.A., Malenka RC. 2007. Synaptic plasticity and addiction. Nat Rev Neurosci 8: 844-858.
60. Kee B.L., Arias J, Montminy MR. 1996. Adaptor-mediated recruitment of RNA polymerase II to a signal-dependent activator. J Biol Chem 271: 2373-2375.
61. Kim T.K., Hemberg M, Gray JM, Costa AM, Bear DM, Wu J, Harmin D.A., Laptewicz M, Barbara-Haley K, Kuersten S, et al. 2010. Widespread transcription at neuronal activity-regulated enhancers. Nature 465: 182-187.
62. Knoll A.T., Carlezon WA Jr. 2010. Dynorphin, stress, and depression. Brain Res 1314: 56-73.
63. Knoll A.T., Meloni EG, Thomas JB, Carroll FI, Carlezon WA Jr. 2007. Anxiolytic-like effects of κ-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 323: 838-845.
64. Knoll A.T., Muschamp JW, Sillivan SE, Ferguson D, Dietz DM, Meloni EG, Carroll FI, Nestler EJ, Konradi C, Carlezon WA Jr. 2011. κ Opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol Psychiatry 70: 425-433.
65. Kobierski L.A., Wong AE, Srivastava S, Borsook D, Hyman SE. 1999. Cyclic AMP-dependent activation of the proenkephalin gene requires phosphorylation of CREB at serine-133 and a Src-related kinase. J Neurochem 73: 129-138.
66. Konradi C., Kobierski LA, Nguyen TV, Heckers S, Hyman SE. 1993. The cAMP-response-element-binding protein interacts, but Fos protein does not interact, with the proenkephalin enhancer in rat striatum. Proc Natl Acad Sci 90: 7005-7009.
67. Konradi C., Cole RL, Heckers S, Hyman SE. 1994. Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J Neurosci 14: 5623-5634.
68. Koob GF. 2010. The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res 1314: 3-14.
69. Koob G.F., Le Moal M. 2008. Addiction and the brain antireward system. Annu Rev Psychol 59: 29-53.
70. Koob G.F., Wall TL, Bloom FE. 1989. Nucleus accumbens as a substrate for the aversive stimulus effects of opiate withdrawal. Psychopharmacology (Berl) 98: 530-534.
71. Land B.B., Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C. 2008. The dysphoric component of stress is encoded by activation of the dynorphin κ-opioid system. J Neurosci 28: 407-414.
72. Larson E.B., Graham DL, Arzaga RR, Buzin N, Webb J, Green TA, Bass CE, Neve RL, Terwilliger EF, Nestler EJ, et al. 2011. Overexpression of CREB in the nucleus accumbens shell increases cocaine reinforcement in self-administering rats. J Neurosci 31: 16447-16457.
73. Liu F.C., Graybiel AM. 1998. Region-dependent dynamics of cAMP response element-binding protein phosphorylation in the basal ganglia. Proc Natl Acad Sci 95: 4708-4713.
74. Lobo M.K., Covington HE 3rd, Chaudhury D, Friedman AK, Sun H., Damez-Werno D, Dietz DM, Zaman S, Koo JW, Kennedy P.J., et al. 2010. Cell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward. Science 330: 385-390.
75. Louilot A., Gonzalez-Mora JL, Guadalupe T, Mas M. 1991. Sex-related olfactory stimuli induce a selective increase in dopamine release in the nucleus accumbens of male rats. Avoltammetric study. Brain Res 553: 313-317.
76. 2+/calmodulindependent protein kinase II in the nucleus accumbens shell enhances behavioral responding to amphetamine. J Neurosci 30: 939-949.
77. Mague S.D., Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y., Stevens WC Jr, Jones RM, Portoghese PS, CarlezonWA Jr. 2003. Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305: 323-330.
78. Maisonneuve I.M., Archer S, Glick SD. 1994. U50,488, a κ opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181: 57-60.
79. Mansour A., Fox CA, Meng F, Akil H, Watson SJ. 1994. κ 1 receptor mRNA distribution in the rat CNS: Comparison to κ receptor binding and prodynorphinmRNA. MolCell Neurosci 5: 124-144.
80. Margolis E.B., Lock H, Chefer VI, Shippenberg TS, Hjelmstad GO, Fields HL. 2006. κ Opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci 103: 2938-2942.
81. Mattson B.J., Bossert JM, Simmons DE, Nozaki N, Nagarkar D, Kreuter JD, Hope BT. 2005. Cocaine-induced CREB phosphorylation in nucleus accumbens of cocaine-sensitized rats is enabled by enhanced activation of extracellular signal-related kinase, but not protein kinase A. J Neurochem 95: 1481-1494.
82. Mayr B., Montminy M. 2001. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2: 599-609.
83. McClung CA, Nestler EJ. 2003. Regulation of gene expression and cocaine reward by CREB and DFosB. NatNeurosci 6: 1208-1215.
84. Meredith GE. 1999. The synaptic framework for chemical signaling in nucleus accumbens. Ann NY Acad Sci 877: 140-156.
85. Mogenson G.J., Jones DL, Yim CY. 1980. From motivation to action: Functional interface between the limbic system and the motor system. Prog Neurobiol 14: 69-97.
86. Molina C.A., Foulkes NS, Lalli E, Sassone-Corsi P. 1993. Inducibility and negative autoregulation of CREM: An alternative promoter directs the expression of ICER, an early response repressor. Cell 75: 875-886.
87. Montminy M.R., Bilezikjian LM. 1987. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature 328: 175-178.
88. Montminy M.R., Sevarino KA, Wagner JA, Mandel G, Goodman RH. 1986. Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. Proc Natl Acad Sci 83: 6682-6686.
89. Morani A.S., Kivell B, Prisinzano TE, Schenk S. 2009. Effect of κ-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacol Biochem Behav 94: 244-249.
90. Muschamp J.W., Van't Veer A, Parsegian A, Gallo MS, Chen M, Neve RL, Meloni EG, Carlezon WA Jr. 2011. Activation of CREB in the nucleus accumbens shell produces anhedonia and resistance to extinction of fear in rats. J Neurosci 31: 3095-3103.
91. Negus S.S., Mello NK, Portoghese PS, Lin CE. 1997. Effects of κ opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 282: 44-55.
92. Newton S.S., Thome J, Wallace TL, Shirayama Y, Schlesinger L, Sakai N, Chen J, Neve R, Nestler EJ, Duman RS. 2002. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci 22: 10883-10890.
93. Ogryzko V.V., Schiltz RL, Russanova V, Howard BH, Nakatani Y. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 953-959.
94. Okaty B.W., Sugino K, Nelson SB. 2011. A quantitative comparison of cell-type-specific microarray gene expression profiling methods in the mouse brain. PLoS ONE 6: e16493.
95. Olive M.F., Cleva RM, Kalivas PW, Malcolm RJ. 2012. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav 100: 801-810.
96. Papai G., Weil PA, Schultz P. 2011. New insights into the function of transcription factor TFIID from recent structural studies. Curr Opin Genet Dev 21: 219-224.
97. Parsons L.H., SmithAD, Justice JB Jr. 1991. Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. Synapse 9: 60-65.
98. Pennartz C.M., Berke JD, Graybiel AM, Ito R, Lansink CS, van der Meer M, Redish AD, Smith KS, Voorn P. 2009. Corticostriatal interactions during learning, memory processing, and decision making. J Neurosci 29: 12831-12838.
99. Pfeiffer A., Brantl V, Herz A, Emrich HM. 1986. Psychotomimesis mediated by κ opiate receptors. Science 233: 774-776.
100. Pliakas A.M., Carlson RR, Neve RL, Konradi C, Nestler EJ, Carlezon WA Jr. 2001. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. J Neurosci 21: 7397-7403.
101. Potter D.N., Damez-Werno D, Carlezon WA Jr, Cohen BM, Chartoff EH. 2011. Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity. Biol Psychiatry 70: 744-753.
102. Radhakrishnan I., Perez-Alvarado GC, Parker D, Dyson HJ, Montminy M.R., Wright PE. 1997. Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB: A model for activator:coactivator interactions. Cell 91: 741-752.
103. Redgrave P., Vautrelle N, Reynolds JN. 2011. Functional properties of the basal ganglia's re-entrant loop architecture: Selection and reinforcement. Neuroscience 198: 138-151.
104. Robertson M.W., Leslie CA, Bennett JP Jr. 1991. Apparent synaptic dopamine deficiency induced by withdrawal from chronic cocaine treatment. Brain Res 538: 337-339.
105. Roitman M.F., Stuber GD, Phillips PE, Wightman RM, Carelli RM. 2004. Dopamine operates as a subsecond modulator of food seeking. J Neurosci 24: 1265-1271.
106. Roitman M.F., Wheeler RA, Carelli RM. 2005. Nucleus accumbens neurons are innately tuned for rewarding and aversive taste stimuli, encode their predictors, and are linked to motor output. Neuron 45: 587-597.
107. Schenk S., Partridge B, Shippenberg TS. 1999. U69593, a κopioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (Berl) 144: 339-346.
108. Schmidt H.D., Duman RS. 2007. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 18: 391-418.
109. Schultz W. 2007. Multiple dopamine functions at different time courses. Annu Rev Neurosci 30: 259-288.
110. Shaywitz A.J., Greenberg ME. 1999. CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68: 821-861.
111. Shieh P.B., Hu SC, Bobb K, Timmusk T, Ghosh A. 1998. Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron 20: 727-740.
112. Shirayama Y., Ishida H, Iwata M, Hazama GI, Kawahara R, Duman RS. 2004. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem 90: 1258-1268.
113. Simpson J.N., McGinty JF. 1995. Forskolin induces preproenkephalin and preprodynorphin mRNA in rat striatum as demonstrated by in situ hybridization histochemistry. Synapse 19: 151-159.
114. Spanagel R., Herz A, Shippenberg TS. 1990. The effects of opioid peptides on dopamine release in the nucleus accumbens: An in vivo microdialysis study. J Neurochem 55: 1734-1740.
115. 2+/calmodulin-dependent protein kinases type II and type IV involves phosphorylation of a site that negatively regulates activity. Genes Dev 8: 2527-2539.
116. Svingos A.L., Colago EE, Pickel VM. 1999. Cellular sites for dynorphin activation of κ-opioid receptors in the rat nucleus accumbens shell. J Neurosci 19: 1804-1813.
117. Swendsen J., Conway KP, Degenhardt L, Glantz M, Jin R, Merikangas K.R., Sampson N, Kessler RC. 2010. Mental disorders as risk factors for substance use, abuse and dependence: Results from the 10-year follow-up of the National Comorbidity Survey. Addiction 105: 1117-1128.
118. 2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20: 709-726.
119. Terwilliger R.Z., Beitner-Johnson D, Sevarino KA, Crain SM, Nestler EJ. 1991. A general role for adaptations in Gproteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res 548: 100-110.
120. Tidey J.W., Miczek KA. 1996. Social defeat stress selectively alters mesocorticolimbic dopamine release: An in vivo microdialysis study. Brain Res 721: 140-149.
121. Todtenkopf M.S., Marcus JF, Portoghese PS, CarlezonWA Jr. 2004. Effects of κ-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl) 172: 463-470.
122. Tomasiewicz H.C., Todtenkopf MS, Chartoff EH, Cohen BM, Carlezon WA Jr. 2008. The κ-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward. Biol Psychiatry 64: 982-988.
123. Turgeon S.M., Pollack AE, Fink JS. 1997. Enhanced CREB phosphorylation and changes in c-Fos and FRA expression in striatum accompany amphetamine sensitization. Brain Res 749: 120-126.
124. Volkow N.D., Fowler JS, Wang GJ, Baler R, Telang F. 2009. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 56 (Suppl 1): 3-8.
125. Voorn P., Vanderschuren LJ, Groenewegen HJ, Robbins TW, Pennartz CM. 2004. Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci 27: 468-474.
126. Wadzinski B.E., Wheat WH, Jaspers S, Peruski LF Jr, Lickteig RL, Johnson GL, Klemm DJ. 1993. Nuclear protein phosphatase 2A dephosphorylates protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation. Mol Cell Biol 13: 2822-2834.
127. Walsh S.L., Strain EC, Abreu ME, Bigelow GE. 2001. Enadoline, a selective κ opioid agonist: Comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 157: 151-162.
128. Weddington W.W., Brown BS, Haertzen CA, Cone EJ, Dax EM, Herning RI, Michaelson BS. 1990. Changes in mood, craving, and sleep during short-term abstinence reported by male cocaine addicts. A controlled, residential study. Arch Gen Psychiatry 47: 861-868.
129. Wee S., Koob GF. 2010. The role of the dynorphin-κ opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl) 210: 121-135.
130. Wheeler R.A., Carelli RM. 2009. Dissecting motivational circuitry to understand substance abuse. Neuropharmacology 56 (Suppl 1): 149-159.
131. Wheeler R.A., Twining RC, Jones JL, Slater JM, Grigson PS, Carelli RM. 2008. Behavioral and electrophysiological indices of negative affect predict cocaine self-administration. Neuron 57: 774-785.
132. Wilkinson M.B., Xiao G, Kumar A, LaPlant Q, Renthal W, Sikder D., Kodadek TJ, Nestler EJ. 2009. Imipramine treatment and resiliency exhibit similar chromatin regulation in the mouse nucleus accumbens in depression models. J Neurosci 29: 7820-7832.
133. Wise RA. 2004. Dopamine, learning and motivation. Nat Rev Neurosci 5: 483-494.
134. Wise RA. 2008. Dopamine and reward: The anhedonia hypothesis 30 years on. Neurotox Res 14: 169-183.
135. Wise R.A., Rompré PP. 1989. Brain dopamine and reward. Annu Rev Psychol 40: 191-225.
136. Witten I.B., Steinberg EE, Lee SY, Davidson TJ, Zalocusky KA, Brodsky M., Yizhar O, Cho SL, Gong S, Ramakrishnan C, et al. 2011. Recombinase-driver rat lines: Tools, techniques, and optogenetic application to dopamine-mediated reinforcement. Neuron 72: 721-733.
137. Yamamoto K.K., Gonzalez GA, Biggs WH III, Montminy MR. 1988. Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB. Nature 334: 494-498.
138. Zhang Y., Butelman ER, Schlussman SD, Ho A, Kreek MJ. 2004. Effect of the endogenous κopioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl) 172: 422-429.
139. Zhang X., Odom DT, Koo SH, Conkright MD, Canettieri G, Best J., Chen H, Jenner R, Herbolsheimer E, Jacobsen E, et al. 2005. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci 102: 4459-4464.